We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




POC Blood Test Can Help Prevent Toxoplasmosis

By LabMedica International staff writers
Posted on 28 Aug 2018
Toxoplasma gondii gains access to human hosts when they eat undercooked contaminated meat or are exposed to material contaminated by feces from an acutely infected cat, which usually goes unrecognized.

Vertical transmission from mother to fetus occurs from primary acute infection during gestation. Congenital infection may result in chorioretinitis, hydrocephalus, epilepsy, and death. Serologic screening during gestation allows early antenatal detection and rapid treatment initiation, with economic and patient outcome benefits.

An international team of scientists led by those at the Pritzker School of Medicine (University of Chicago, Chicago, IL, USA) collected and tested 244 samples from 205 individuals in the USA, France and Morocco. Each person of unknown serologic status underwent venipuncture, and status was confirmed either with ARCHITECT Toxo-IgG and IgM system in the Lyon, France Reference Laboratory (n = 95 persons), or for 39 Moroccan patients with Platelia Toxo IgG and IgM system.

The participants provided whole blood via fingerstick. Participants’ fingers were compressed, suffusing the tip, and cleaned with an alcohol wipe. A standard lancet was used for fingerstick. Capillary tubes allowed collection of 30 μL of blood, which was directly applied to the point-of-care (POC) Toxoplasma ICT IgG–IgM–BK test, followed by application of four drops of buffer, provided in the kit. Tests were interpreted at 20 to 30 minutes by individuals performing tests and photographed for later interpretation by two individuals unaware of the subjects’ identity and serologic status.

The scientists reported that a total of 205 persons (244 samples) had their serologic status for T. gondii assessed using the whole blood-variant test and was confirmed using their National Collaborative Chicago-Based Congenital Toxoplasmosis Study (NCCCTS) records (n = 71), or concurrent standard laboratory testing (n = 134). Overall, 101 samples proved seropositive, including five from acutely infected individuals who had IgM/IgG antibodies against T. gondii, while 143 were seronegative. The whole-blood test proved highly sensitive and specific, with a sensitivity of 100% and specificity of 100%. Whole blood, serum-variant, and reference testing demonstrated 100% concordance. Of note, individuals with lower levels of anti-Toxoplasma antibodies infected at remote times and with lower titers were positive in the POC test in the range detected by gold-standard test.

The test is also inexpensive as it costs USD 4.0 to USD 5.0 per test. Pregnant women at risk should be tested eight to 10 times, once a month during pregnancy, beginning in the 12th week, then once more four to six weeks after delivery. Total cost for repeated tests is about USD 40.00 to USD 50.00. Hospitals and clinics in developed countries charge substantially more.

Rima McLeod, MD, a professor of ophthalmology and lead author of the study, said, “The test is sensitive and specific, quick and easy to perform, equipment-free, and easily utilized. Results are available in half an hour while the patient is seeing the doctor. A positive result can be confirmed quickly, so health care providers can immediately begin treatment.” The study was published on August 16, 2018, in the journal PLOS Neglected Tropical Diseases.

Related Links:
Pritzker School of Medicine


Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Centromere B Assay
Centromere B Test
New
Coagulation Analyzer
CS-2400
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.